KEY POINTS
  • GoodRx is in sale talks with several interested parties and could fetch up to $3 billion.
  • GoodRx, which offers a way for people with no or expensive health insurance to save on prescriptions, is on track for $100 million in EBITDA this year, a person said.
  • The company was valued around $300 million before the last time it raised money in 2014.

Health-tech start-up GoodRx is in talks to be acquired for at least $1.5 billion, but could fetch as high as $3 billion, according several people familiar.

Health distribution giant McKesson was among the companies taking a look, one person said, but will probably not be the buyer. The identity of the other potential buyers could not be learned. No transaction is imminent and the talks may not result in a deal.